Gujarat-based specialty chemicals maker of advanced intermediates for pharma, agrochem & oil & gas
Price
Market Cap
Sector
Commodities
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 9 | 10 | 113 | 125 | 133 | 133 | 133 | 133 |
| Reserves | 70 | 164 | 274 | 1.1k | 1.9k | 2.1k | 2.2k | 2.3k |
| Borrowings | 172 | 211 | 291 | 16 | 144 | 137 | 165 | 356 |
| Other Liabilities | 50 | 67 | 92 | 120 | 143 | 199 | 275 | 237 |
| Total Liabilities | 300 | 453 | 770 | 1.4k | 2.4k | 2.6k | 2.8k | 3.0k |
| AssetsFixed Assets | 129 | 216 | 257 | 646 | 743 | 989 | 1.1k | 1.4k |
| CWIP | 17 | 0 | 58 | 37 | 219 | 340 | 529 | 474 |
| Investments | 0 | 22 | 17 | 1 | 0 | 100 | 100 | 100 |
| Other Assets | 154 | 214 | 438 | 695 | 1.4k | 1.1k | 1.1k | 1.0k |
| Total Assets | 300 | 453 | 770 | 1.4k | 2.4k | 2.6k | 2.8k | 3.0k |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 23 | 18 | 23 | -5 | -7 | -2 | 118 | 146 |
| Cash from Investing | -13 | -48 | -77 | -151 | -348 | -399 | -415 | -590 |
| Cash from Financing | -10 | 33 | 55 | 169 | 439 | 854 | -19 | 211 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | 10 | -30 | -53 | -157 | -363 | -305 | -304 | -375 |
| FCF Margin | — | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (89.4×) and current (112.6×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 9.9% growth and a 89× exit, ₹1475 only delivers your return if you pay ₹804. The price is currently baking in 23% growth.
EPS grows 9.9%/yr for 5 years, then fades to 6% over 2, exits at 89×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 9.9% | 14.40 |
| FY28 | 9.9% | 15.82 |
| FY29 | 9.9% | 17.39 |
| FY30 | 9.9% | 19.11 |
| FY31 | 9.9% | 21.00 |
| FY32 | 8.0% ·fade | 22.67 |
| FY33 | 6.0% ·fade | 24.03 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.